Navigation Links
Three U.S. Hospitals Reduce Costly Catheter-Related Bloodstream Infections
Date:9/27/2010

ed needleless connector technology designed to help health care providers. MaxPlus and MaxGuard® brands of needleless IV connectors are clinically shown to help reduce CRBSIs, reduce catheter occlusions and improve outcomes, costs and enhance safety.

CareFusion recently added these brands to the infusion business portfolio through the acquisition of Medegen in April 2010.

About CareFusion

CareFusion (NYSE: CFN) is a global corporation serving the health care industry with products and services that help hospitals measurably improve the safety and quality of care. The company develops market-leading technologies including Alaris® IV pumps, Pyxis® automated dispensing and patient identification systems, AVEA®, AirLife™ and LTV® series ventilation and respiratory products, ChloraPrep® products, MedMined™ services for infection surveillance, NeuroCare neurological monitoring and diagnostic products, V. Mueller® surgical instruments, and an extensive line of products that support interventional medicine. CareFusion employs more than 15,000 people across its global operations. More information may be found at www.carefusion.com.

(1) O'Grady, N.P., Alexander, M., Dellinger, E.P., Gerberding, J.L., Heard, S.O., Maki, D.G., Masur, H., McCormick, R.D., Mermel, L.A., Pearson, M.L., Raad, I.I., Randolph, A., Weinstein, R.A. "Guidelines for the Prevention of Intravascular Catheter-related Infections." The Centers for Disease Control, August 9, 2002, Vol. 51, No. RR10, pp. 1-26.

(2) O'Grady, N.P., Alexander, M., Dellinger, E.P., Gerberding, J.L., Heard, S.O., Maki, D.G., Masur, H., McCormick, R.D., Mermel, L.A., Pearson, M.L., Raad, I.I., Randolph, A., Weinstein, R.A. "Guidelines for the Prevention of Intravascular Catheter-related Infections." The Centers f
'/>"/>

SOURCE CareFusion Corp.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ViroPharma to Present at Three Upcoming Healthcare Conferences
2. Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
3. Versatility of 454 Sequencing(TM) Demonstrated in Three Publications in Science Last Week
4. Data from Three Clinical Trials for Perforomist(TM) Inhalation Solution to be Presented at CHEST 2007 on October 24, 2007
5. Boston Scientific Carotid Artery Stenting Trials Produce Positive Three-Year Results
6. Long-Term Data from a Landmark Phase III Trial Show Survival Benefit at Three- and Four-Years in Patients with Glioblastoma multiforme
7. Despite Serious Health Risks, One in Three Adults with Heart Disease Does Not Believe They Need a Flu Shot This Year
8. Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent
9. TCS Healthcare Technologies Releases Three New Clinical Care Programs Within ACUITY
10. Three Year Analysis of Treatment Efficacy, Cosmesis, and Toxicity Support use of the Hologic Mammosite Radiation Therapy System
11. Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... Sept. 22, 2014  Neuralstem, Inc. (NYSE MKT: CUR) announced ... at Emory University, presented long-term follow up data on ... cells in the treatment of amyotrophic lateral sclerosis (ALS ... occurred at the Annual Symposium on ALS of the ... on Friday, and was not open to the public, ...
(Date:9/22/2014)... , Sept. 22, 2014  Olympus, a ... solutions for medical and surgical procedures, among other ... deal with Munich -based Brainlab ... ® Navigation. This agreement applies to the ... cross-disciplinary U.S. sales and all distribution outside the ...
(Date:9/22/2014)... , Sept. 22, 2014  Inovio Pharmaceuticals, Inc. ... has initiated a phase I clinical trial in ... the safety, tolerability, and immunogenicity of INO-3106. This ... causes most aerodigestive cancers. Aerodigestive cancers ... cords, and parts of the esophagus and windpipe. ...
Breaking Medicine Technology:Neuralstem ALS Investigator Presents Long-Term Follow Up Phase I Data 2Neuralstem ALS Investigator Presents Long-Term Follow Up Phase I Data 3Neuralstem ALS Investigator Presents Long-Term Follow Up Phase I Data 4Olympus Partners with Brainlab as Exclusive Distributor for ENT Products in U.S. Market 2Olympus Partners with Brainlab as Exclusive Distributor for ENT Products in U.S. Market 3Olympus Partners with Brainlab as Exclusive Distributor for ENT Products in U.S. Market 4Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 2Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 3Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 4
... , , DALLAS , February ... and Central Labs events present Advanced,Biomarker Strategies in Oncology Drug Development. ... from February 4-5, 2010 . This,event is FREE for executives ... This two-day program focuses exclusively on the latest developments in,oncology biomarkers. ...
... RESEARCH TRIANGLE PARK, N.C. , Jan. 29 ... the U.S. Food and Drug Administration has approved ... in patients ages 13 years and older with primary generalized ... XR is approved for partial onset seizures ...
Cached Medicine Technology:MarketsandMarkets Partners With IIR USA for Their Event 'Advanced Biomarker Strategies in Oncology Drug Development' 2MarketsandMarkets Partners With IIR USA for Their Event 'Advanced Biomarker Strategies in Oncology Drug Development' 3FDA Approves Once-A-Day Lamictal(R)XR(TM) as Add-On Epilepsy Therapy for Primary Generalized Tonic-Clonic Seizures 2FDA Approves Once-A-Day Lamictal(R)XR(TM) as Add-On Epilepsy Therapy for Primary Generalized Tonic-Clonic Seizures 3FDA Approves Once-A-Day Lamictal(R)XR(TM) as Add-On Epilepsy Therapy for Primary Generalized Tonic-Clonic Seizures 4FDA Approves Once-A-Day Lamictal(R)XR(TM) as Add-On Epilepsy Therapy for Primary Generalized Tonic-Clonic Seizures 5FDA Approves Once-A-Day Lamictal(R)XR(TM) as Add-On Epilepsy Therapy for Primary Generalized Tonic-Clonic Seizures 6FDA Approves Once-A-Day Lamictal(R)XR(TM) as Add-On Epilepsy Therapy for Primary Generalized Tonic-Clonic Seizures 7
(Date:9/22/2014)... 22, 2014 As concerns about ... power morcellators ( http://www.gynecaremorcellatorlawsuit.com/ ) in gynecological surgeries ... detailing the continued use of uterine morcellation by ... specifically discouraged these procedures. According to The Wall ... cancer risks associated with power morcellators are overblown, ...
(Date:9/22/2014)... CareFlight Air & Mobile Services ... new AS365 N3+ Dauphin, the latest version of Airbus ... is based at Miami Valley Hospital in ... medical transport helicopters. , “We have a lot of ... Vice President, Emergency, Trauma, and CareFlight. “We’ve been operating ...
(Date:9/22/2014)... Diego CA (PRWEB) September 22, 2014 ... significantly expand its work to equip women around the ... on poverty. Through the Women Empowered (WE) Initiative ... will now join community-led groups to pool their savings, ... , “Women are the solution to ending poverty in ...
(Date:9/22/2014)... September 22, 2014 The New York ... of Surgery at the Icahn School of Medicine at ... York Group for Plastic Surgery gives residents of New ... a team of world-renowned plastic surgeons performing innovative reconstructive ... Salzberg, MD, who led NYGPS, was named the Director ...
(Date:9/22/2014)... WHO: LiveOps, Inc., the global leader ... , WHAT: The 10th annual Customer Response Summit ... the connected consumer. Constant change in technology and ... and opportunities for customer experience executives. The Summit ... network and learn from fellow attendees, speakers and ...
Breaking Medicine News(10 mins):Health News:Power Morcellator News: Bernstein Liebhard LLP Notes New Report Detailing Continued Use of Uterine Morcellation Despite FDA Warning 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes New Report Detailing Continued Use of Uterine Morcellation Despite FDA Warning 3Health News:Power Morcellator News: Bernstein Liebhard LLP Notes New Report Detailing Continued Use of Uterine Morcellation Despite FDA Warning 4Health News:Miami Valley Hospital CareFlight begins Service with AS365 N3+ 2Health News:Miami Valley Hospital CareFlight begins Service with AS365 N3+ 3Health News:PCI Announces New Effort to Empower 250,000 Women Worldwide at 2014 Clinton Global Initiative (CGI) Annual Meeting 2Health News:PCI Announces New Effort to Empower 250,000 Women Worldwide at 2014 Clinton Global Initiative (CGI) Annual Meeting 3Health News:The New York Group for Plastic Surgery Joins Mount Sinai Doctors 2Health News:The New York Group for Plastic Surgery Joins Mount Sinai Doctors 3Health News:LiveOps To Lead Panel Discussion At Customer Response Summit Memphis 2
... YORK, Oct. 8 "Fluoridation of drinking,water is scientifically ... initiative or program," says the Canadian Association of Physicians,for ... CAPE is Canada,s leading voice on environmental health issues., ... fluoridation of public,drinking water in several communities in Alberta, ...
... New interim guidance,that outlines how to become a ... U.S. Department of Health and Human Services., ... Safety Act),authorized the creation of PSOs to improve ... patient safety events. By providing both privilege,and confidentiality, ...
... appears to sustain insulin production in the newly diagnosed. ... have developed a vaccine that may change the way ... diagnosed with type 1 diabetes. , "By a very ... save [a person,s] own insulin secretion, which may be ...
... N.J., Oct. 8 Quest Diagnostics,Incorporated (NYSE: DGX ... services, announced today that its third-quarter,2008 results will be ... and that it will hold its quarterly conference call ... ET on that day., The public may access ...
... The following statement,of Matthew L. Myers was released today ... reports, R.J. Reynolds has announced plans to,test-market three new ... "fresh" and "mellow" flavors and have slick, colorful,packaging similar ... Orbs,these new products also carry the name of RJR,s ...
... HOLE, MA Osamu Shimomura, a senior scientist emeritus ... has been awarded the Nobel Prize in Chemistry for ... the most important tools in contemporary science and medicine ... Shimomura shares the prize, which was announced early today ...
Cached Medicine News:Health News:Physicians' Group Rejects Fluoridation 2Health News:HHS Issues Interim Guidance for Patient Safety Organizations 2Health News:New Vaccine May Help Type 1 Diabetics in Future 2Health News:New Vaccine May Help Type 1 Diabetics in Future 3Health News:Quest Diagnostics to Release Third Quarter 2008 Financial Results 2Health News:R.J. Reynolds' New Smokeless Products Will Appeal to Children and Show Need for FDA Regulation of Tobacco Products 2Health News:MBL scientist Osamu Shimomura wins Nobel Prize for discovery of green fluorescent protein 2Health News:MBL scientist Osamu Shimomura wins Nobel Prize for discovery of green fluorescent protein 3
The first book to translate key medical data into clear guidelines capturing the highest treatment standards for heart disease....
DxRxValv contains tables and figures to summarize important clinical data and current professional society recommendations. This handy manual details precise, up-to-date information for diagnosis and...
... Dx/Rx: Coronary Thrombosis ... flowcharts which facilitate transformation ... protocols from static images ... support tools. Details precise, ...
Cardiology Intensive Board Review is geared specifically to candidates taking the Cardiovascular Boards and the Cardiovascular section of the Internal Medicine Boards....
Medicine Products: